{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T01:11:57Z","timestamp":1767143517363,"version":"build-2238731810"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100019944","name":"Sanofi-Aventis Deutschland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019944","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s13300-024-01670-y","type":"journal-article","created":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T03:56:59Z","timestamp":1733111819000},"page":"121-134","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety and Effectiveness of Glargine 300 U\/ml After Switching from Basal Insulins in Patients with Type\u00a01 Diabetes: COMET-T Study"],"prefix":"10.1007","volume":"16","author":[{"given":"Stefan","family":"G\u00f6lz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7854-4233","authenticated-orcid":false,"given":"Julia K.","family":"Mader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Bilz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Kenzler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Danne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,2]]},"reference":[{"issue":"12","key":"1670_CR1","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1007\/s00125-021-05568-3","volume":"64","author":"RIG Holt","year":"2021","unstructured":"Holt RIG, DeVries JH, Hess-Fischl A, Hirsch IB, Kirkman MS, Klupa T, Ludwig B, N\u00f8rgaard K, Pettus J, Renard E, Skyler JS, Snoek FJ, Weinstock RS, Peters AL. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2021;64(12):2609\u201352.","journal-title":"Diabetologia"},{"key":"1670_CR2","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee. 6. Glycemic goals and hypoglycemia: Standards of Care in Diabetes\u20142024. Diabetes Care 2024;47(Suppl. 1):S111\u201325.","DOI":"10.2337\/dc24-S006"},{"issue":"8","key":"1670_CR3","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.2337\/dci19-0028","volume":"42","author":"T Battelino","year":"2019","unstructured":"Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, Bosi E, Buckingham BA, Cefalu WT, Close KL, Cobelli C, Dassau E, DeVries JH, Donaghue KC, Dovc K, Doyle FJ, Garg S, Grunberger G, Heller S, Heinemann L, Hirs IB, Hovorka R, Jia W, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019;42(8):1593\u2013603.","journal-title":"Diabetes Care"},{"issue":"12","key":"1670_CR4","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1007\/s00125-012-2708-9","volume":"55","author":"T Battelino","year":"2012","unstructured":"Battelino T, Conget I, Olsen B, et al. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomized controlled trial. Diabetologia. 2012;55(12):3155\u201362.","journal-title":"Diabetologia"},{"issue":"4","key":"1670_CR5","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1001\/jama.2016.19975","volume":"317","author":"RW Beck","year":"2017","unstructured":"Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA. 2017;317(4):371\u20138.","journal-title":"JAMA"},{"issue":"10128","key":"1670_CR6","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/S0140-6736(18)30297-6","volume":"391","author":"L Heinemann","year":"2018","unstructured":"Heinemann L, Freckmann G, Ehrmann D, et al. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. Lancet. 2018;391(10128):1367\u201377.","journal-title":"Lancet"},{"issue":"10057","key":"1670_CR7","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1016\/S0140-6736(16)31535-5","volume":"388","author":"J Bolinder","year":"2016","unstructured":"Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kr\u00f6ger J, Weitgasser R. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. 2016;388(10057):2254\u201363.","journal-title":"Lancet"},{"issue":"6","key":"1670_CR8","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1177\/193229680800200618","volume":"2","author":"L Monnier","year":"2008","unstructured":"Monnier L, Colette C, Owens DR. Glycemic variability: the third component of the dysglycemia in diabetes. Is it important? How to measure it? J Diabetes Sci Technol. 2008;2(6):1094\u2013100.","journal-title":"J Diabetes Sci Technol"},{"key":"1670_CR9","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1089\/dia.2018.0384","volume":"21","author":"NC Foster","year":"2019","unstructured":"Foster NC, Beck RW, Miller KM, et al. State of type 1 diabetes management and outcomes from the T1D exchange in 2016\u20132018. Diabetes Technol Ther. 2019;21:66\u201372.","journal-title":"Diabetes Technol Ther"},{"key":"1670_CR10","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/dom.12416","volume":"17","author":"RH Becker","year":"2015","unstructured":"Becker RH, Nowotny I, Teichert L, et al. Low within- and between-day variability in exposure to new insulin glargine 300 U\/ml. Diabetes Obes Metab. 2015;17:261\u20137.","journal-title":"Diabetes Obes Metab"},{"key":"1670_CR11","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s40262-014-0165-y","volume":"53","author":"H Haahr","year":"2014","unstructured":"Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet. 2014;53:787\u2013800.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1670_CR12","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/dom.13048","volume":"20","author":"PD Home","year":"2018","unstructured":"Home PD, Bergenstal RM, Bolli GB, Ziemen M, Rojeski M, Espinasse M, et al. Glycemic control and hypoglycemia during 12 months of randomized treatment with insulin glargine 300 U\/ml versus glargine 100 U\/ml in people with type 1 diabetes (EDITION 4). Diabetes Obes Metab. 2018;20(1):121\u20138.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"1670_CR13","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.2337\/dc15-0249","volume":"38","author":"PD Home","year":"2015","unstructured":"Home PD, Bergenstal RM, Bolli GB, Ziemen M, Rojesk M, Espinasse M, et al. New insulin glargine 300 units\/ml versus glargine 100 units\/ml in people with type 1 diabetes: a randomized, phase 3a, open-label clinical trial (EDITION 4). Diabetes Care. 2015;38(12):2217\u201325.","journal-title":"Diabetes Care"},{"issue":"4","key":"1670_CR14","doi-asserted-by":"publisher","first-page":"554","DOI":"10.2337\/dc16-0684","volume":"40","author":"RM Bergenstal","year":"2017","unstructured":"Bergenstal RM, Bailey TS, Rodbard D, Ziemen M, Guo H, Muehlen-Bartmer I, et al. Comparison of insulin glargine 300 units\/ml and 100 units\/ml in adults with type 1 diabetes: continuous glucose monitoring profiles and variability using morning or evening injections. Diabetes Care. 2017;40(4):554\u201360.","journal-title":"Diabetes Care"},{"issue":"5","key":"1670_CR15","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s40262-016-0464-6","volume":"56","author":"JN Clements","year":"2017","unstructured":"Clements JN, Threatt T, Ward E, Shealy KM. Clinical pharmacokinetics and pharmacodynamics of insulin glargine 300 U\/ml. Clin Pharmacokinet. 2017;56(5):449\u201358.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"1670_CR16","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1111\/dom.14109","volume":"22","author":"T Danne","year":"2020","unstructured":"Danne T, Matsuhisa M, Sussebach C, Goyeau H, Lauand F, Niemoeller E, Bolli GB. Lower risk of severe hypoglycemia with insulin glargine 300 U\/ml versus glargine 100 U\/ml in participants with type 1 diabetes: a meta-analysis of 6-month phase 3 clinical trials. Diabetes Obes Metab. 2020;22(10):1880\u20135.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"1670_CR17","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.diabet.2018.02.002","volume":"44","author":"R Roussel","year":"2018","unstructured":"Roussel R, Ritzel R, Boelle-Le Corfec E, et al. Clinical perspectives from the BEGIN and EDITION programmes: trial-level meta-analyses outcomes with either degludec or glargine 300 U\/ml vs glargine 100 U\/ml in T2DM. Diabetes Metab. 2018;44(5):402\u20139.","journal-title":"Diabetes Metab"},{"key":"1670_CR18","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/dom.12485","volume":"17","author":"R Ritzel","year":"2015","unstructured":"Ritzel R, Roussel R, Bolli GB, et al. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U\/ml versus glargine 100 U\/ml in people with type 2 diabetes. Diabetes Obes Metab. 2015;17:859\u201367.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"1670_CR19","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/17446651.2018.1469405","volume":"13","author":"P Oriot","year":"2018","unstructured":"Oriot P, Jeremie W, Buysschaert M. Outcomes of glycemic control in type 1 diabetic patient switched from basal insulin glargine 100 U\/ml to glargine 300 U\/ml in real life. Exp Rev Endocrinol Metab. 2018;13(3):167\u201371.","journal-title":"Exp Rev Endocrinol Metab"},{"key":"1670_CR20","unstructured":"Good Epidemiological Practice (GEP). Proper conduct in epidemiology research. IEA European Federation; 2007."},{"issue":"11","key":"1670_CR21","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(21)00246-1","volume":"9","author":"B Van der Schueren","year":"2021","unstructured":"Van der Schueren B, Ellis D, Faradji RN, et al. Obesity in people living with type 1 diabetes. Lancet Diabetes Endocrinol. 2021;9(11):776\u201385.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"1670_CR22","doi-asserted-by":"publisher","first-page":"832","DOI":"10.2337\/dc16-1769","volume":"40","author":"L Monnier","year":"2017","unstructured":"Monnier L, Colette C, Wojtusciszyn A, et al. Toward defining the threshold between low and high glucose variability in diabetes. Diabetes Care. 2017;40(7):832\u20138.","journal-title":"Diabetes Care"},{"issue":"3","key":"1670_CR23","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S2213-8587(18)30136-0","volume":"7","author":"A Ceriello","year":"2019","unstructured":"Ceriello A, Monnier L, Owens D. Glycaemic variability in diabetes: clinical and therapeutic implications. Lancet Diabetes Endocrinol. 2019;7(3):221\u201330.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"1670_CR24","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s13300-020-00982-z","volume":"12","author":"L Laviola","year":"2021","unstructured":"Laviola L, Porcellati F, Bruttomesso D, Larosa M, Rossi MC, Nicolucci A, on behalf of the RESTORE-1 Study Group. Comparative effectiveness of switching from first-generation basal insulin to glargine 300 U\/ml or degludec 100 U\/ml in type 1 diabetes: the RESTORE-1 study. Diabetes Ther. 2021;12(2):509\u201325.","journal-title":"Diabetes Ther"},{"key":"1670_CR25","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1007\/s13300-021-01153-4","volume":"12","author":"I Conget","year":"2021","unstructured":"Conget I, Mangas MA, Morales C, Caro J, Gimenez M, Borrell M, Delgado E. Effectiveness and safety of insulin glargine 300 U\/ml in comparison with insulin degludec 100 U\/ml evaluated with continuous glucose monitoring in adults with type 1 diabetes and suboptimal glycemic control in routine clinical practice: the OneCARE Study. Diabetes Ther. 2021;12:2993\u20133009.","journal-title":"Diabetes Ther"}],"updated-by":[{"DOI":"10.1007\/s13300-025-01771-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000}}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-024-01670-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-024-01670-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-024-01670-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T01:12:04Z","timestamp":1757121124000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-024-01670-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,2]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["1670"],"URL":"https:\/\/doi.org\/10.1007\/s13300-024-01670-y","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,2]]},"assertion":[{"value":"24 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s13300-025-01771-2","URL":"https:\/\/doi.org\/10.1007\/s13300-025-01771-2","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Thomas Danne has received speaker fees and research support from or has consulted for Abbott, AstraZeneca, Boehringer Ingelheim, Dexcom, Eli Lilly, Medtronic, Novo Nordisk, Provention Bio, Roche, Sanofi, and Vertex and is a shareholder of DreaMed Ltd. Stefan G\u00f6lz has received speaker fees and research support from or has consulted for Abbott, Ascencia, Novo Nordisk, Novartis, Sanofi, Astra Zeneca, MSD, Berlin Chemia, Lilly, Boehringer Ingelheim, Johnson & Johnson, Medical Tribune, Dexcom, Roche, Menarini, Santis, EvivaMed. Julia Mader has received research support from A. Menarini Diagnostics, Novo Nordisk, Sanofi; Advisory Board: Abbott Diabetes Care, Becton\u2013Dickinson\/Embecta, Eli Lilly, Medtronic, Novo Nordisk, PharmaSens, Roche Diabetes Care, Sanofi, Viatris; speaker fees from Abbott Diabetes Care, A. Menarini Diagnostics, Becton Dickinson\/Embecta, Boehringer-Ingelheim, Eli Lilly, MedTrust, Novo Nordisk, Roche Diabetes Care, Sanofi, Servier, Ypsomed; Shareholder of decide Clinical Software GmbH. Stefan Bilz has received speaker\u2019s fees from or consulted for Amgen, Sanofi, Novartis, Bayer, Daiichi-Sankyo, Novo Nordisk; travel support from Novo Nordisk. Julia Kenzler is an employee of Sanofi-Aventis Deutschland GmbH.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in accordance with the Helsinki Declaration of 1964. The study received approval from the institutional review board or ethics committee at each participating center. Approval reference numbers were BASEC-Nr. 2020-01997, F-2020-106, 32-605 ex 19\/2. A formal written informed consent was obtained from all patients prior to their enrolment in the study. Permissions were obtained to use the DTSQ questionnaire in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}